Short Interest in ENDRA Life Sciences Inc. (NASDAQ:NDRA) Grows By 163.6%

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 154,773 shares, a growth of 163.6% from the February 12th total of 58,719 shares. Currently, 22.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 511,270 shares, the short-interest ratio is presently 0.3 days. Based on an average daily trading volume, of 511,270 shares, the short-interest ratio is presently 0.3 days. Currently, 22.8% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Ascendiant Capital Markets decreased their target price on shares of ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, December 8th. Wall Street Zen upgraded ENDRA Life Sciences to a “sell” rating in a report on Saturday, November 22nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $30.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises approximately 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. Altium Capital Management LLC owned about 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. 1.19% of the stock is owned by institutional investors and hedge funds.

ENDRA Life Sciences Trading Down 2.0%

NASDAQ:NDRA traded down $0.07 during trading hours on Wednesday, hitting $3.45. The company’s stock had a trading volume of 22,849 shares, compared to its average volume of 133,998. The stock has a fifty day moving average of $4.06 and a 200-day moving average of $4.92. The stock has a market capitalization of $2.60 million, a P/E ratio of -0.13 and a beta of -0.08. ENDRA Life Sciences has a 52-week low of $2.90 and a 52-week high of $11.96.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.